Dimenhydrinate

Vertigo, Vertigo, Gastrointestinal distress + 12 more

Treatment

13 FDA approvals

20 Active Studies for Dimenhydrinate

What is Dimenhydrinate

Dimenhydrinate

The Generic name of this drug

Treatment Summary

Dimehydrinate is a medication that helps to prevent nausea, vomiting, and dizziness caused by motion sickness. It is a combination of an antihistamine called diphenhydramine and 8-chlorotheophylline in a salt form. It works by blocking histamine receptors in the vestibular system and blocking adenosine receptors. When taken in large doses, it can cause hallucinations, excitement, incoordination, and disorientation. Dimehydrinate was approved by the FDA in 1972.

Motion Sickness

is the brand name

image of different drug pills on a surface

Dimenhydrinate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Motion Sickness

Dimenhydrinate

1992

1

Approved as Treatment by the FDA

Dimenhydrinate, also known as Motion Sickness, is approved by the FDA for 13 uses such as Nausea and Post Operative Nausea and Vomiting (PONV) .

Nausea

Post Operative Nausea and Vomiting (PONV)

Prevention of Nausea Associated With Motion Sickness

Motion Sickness

prophylaxis of radiation therapy induced nausea and vomiting

Labyrinthine disorder

Airsickness

radiation therapy induced nausea and vomiting

Nausea

Nausea

Labyrinthitis

Motion Sickness

Acrodynia

Effectiveness

How Dimenhydrinate Affects Patients

Dimenhydrinate is a drug used to prevent and treat nausea, vomiting, or dizziness related to motion sickness. It works for 4-8 hours. Patients should be aware that this drug can cause drowsiness and should avoid drinking alcohol or taking other sedatives while taking it. People should also be careful when driving or operating heavy machinery.

How Dimenhydrinate works in the body

Dimenhydrinate works by combining two active ingredients, diphenhydramine and 8-chlorotheophylline. Diphenhydramine is thought to reduce dizziness by blocking certain receptors, while 8-chlorotheophylline may help to increase alertness by blocking adenosine receptors. The exact way these ingredients interact is not yet known.

When to interrupt dosage

The advised measure of Dimenhydrinate is contingent on the determined situation, including Acrodynia, Motion Sickness and Nausea. The quantity of dosage is subject to the system of delivery (e.g. Oral or Tablet, extended release) as detailed in the table hereunder.

Condition

Dosage

Administration

Vertigo

, 50.0 mg, 25.0 mg, 50.0 mg/mL, 15.0 mg, 100.0 mg, 75.0 mg, 15.0 mg/mL, 10.0 mg/mL, 3.0 mg/mL, 250.0 mg/mL

Oral, Tablet, Tablet - Oral, , Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup, Syrup - Oral, Suppository, Rectal, Suppository - Rectal, Solution, Solution - Intramuscular, Liquid, Liquid - Oral, Intramuscular, Intravenous, Liquid - Intramuscular; Intravenous, Liquid - Intravenous, Capsule - Oral, Capsule, Tablet, multilayer - Oral, Tablet, multilayer, Solution - Intramuscular; Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Oral

Airsickness

, 50.0 mg, 25.0 mg, 50.0 mg/mL, 15.0 mg, 100.0 mg, 75.0 mg, 15.0 mg/mL, 10.0 mg/mL, 3.0 mg/mL, 250.0 mg/mL

Oral, Tablet, Tablet - Oral, , Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup, Syrup - Oral, Suppository, Rectal, Suppository - Rectal, Solution, Solution - Intramuscular, Liquid, Liquid - Oral, Intramuscular, Intravenous, Liquid - Intramuscular; Intravenous, Liquid - Intravenous, Capsule - Oral, Capsule, Tablet, multilayer - Oral, Tablet, multilayer, Solution - Intramuscular; Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Oral

Motion Sickness

, 50.0 mg, 25.0 mg, 50.0 mg/mL, 15.0 mg, 100.0 mg, 75.0 mg, 15.0 mg/mL, 10.0 mg/mL, 3.0 mg/mL, 250.0 mg/mL

Oral, Tablet, Tablet - Oral, , Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup, Syrup - Oral, Suppository, Rectal, Suppository - Rectal, Solution, Solution - Intramuscular, Liquid, Liquid - Oral, Intramuscular, Intravenous, Liquid - Intramuscular; Intravenous, Liquid - Intravenous, Capsule - Oral, Capsule, Tablet, multilayer - Oral, Tablet, multilayer, Solution - Intramuscular; Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Oral

Nausea and Vomiting

, 50.0 mg, 25.0 mg, 50.0 mg/mL, 15.0 mg, 100.0 mg, 75.0 mg, 15.0 mg/mL, 10.0 mg/mL, 3.0 mg/mL, 250.0 mg/mL

Oral, Tablet, Tablet - Oral, , Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup, Syrup - Oral, Suppository, Rectal, Suppository - Rectal, Solution, Solution - Intramuscular, Liquid, Liquid - Oral, Intramuscular, Intravenous, Liquid - Intramuscular; Intravenous, Liquid - Intravenous, Capsule - Oral, Capsule, Tablet, multilayer - Oral, Tablet, multilayer, Solution - Intramuscular; Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Oral

Morning Sickness

, 50.0 mg, 25.0 mg, 50.0 mg/mL, 15.0 mg, 100.0 mg, 75.0 mg, 15.0 mg/mL, 10.0 mg/mL, 3.0 mg/mL, 250.0 mg/mL

Oral, Tablet, Tablet - Oral, , Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup, Syrup - Oral, Suppository, Rectal, Suppository - Rectal, Solution, Solution - Intramuscular, Liquid, Liquid - Oral, Intramuscular, Intravenous, Liquid - Intramuscular; Intravenous, Liquid - Intravenous, Capsule - Oral, Capsule, Tablet, multilayer - Oral, Tablet, multilayer, Solution - Intramuscular; Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Oral

Nausea

, 50.0 mg, 25.0 mg, 50.0 mg/mL, 15.0 mg, 100.0 mg, 75.0 mg, 15.0 mg/mL, 10.0 mg/mL, 3.0 mg/mL, 250.0 mg/mL

Oral, Tablet, Tablet - Oral, , Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup, Syrup - Oral, Suppository, Rectal, Suppository - Rectal, Solution, Solution - Intramuscular, Liquid, Liquid - Oral, Intramuscular, Intravenous, Liquid - Intramuscular; Intravenous, Liquid - Intravenous, Capsule - Oral, Capsule, Tablet, multilayer - Oral, Tablet, multilayer, Solution - Intramuscular; Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Oral

radiation therapy induced nausea and vomiting

, 50.0 mg, 25.0 mg, 50.0 mg/mL, 15.0 mg, 100.0 mg, 75.0 mg, 15.0 mg/mL, 10.0 mg/mL, 3.0 mg/mL, 250.0 mg/mL

Oral, Tablet, Tablet - Oral, , Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup, Syrup - Oral, Suppository, Rectal, Suppository - Rectal, Solution, Solution - Intramuscular, Liquid, Liquid - Oral, Intramuscular, Intravenous, Liquid - Intramuscular; Intravenous, Liquid - Intravenous, Capsule - Oral, Capsule, Tablet, multilayer - Oral, Tablet, multilayer, Solution - Intramuscular; Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Oral

Labyrinthitis

, 50.0 mg, 25.0 mg, 50.0 mg/mL, 15.0 mg, 100.0 mg, 75.0 mg, 15.0 mg/mL, 10.0 mg/mL, 3.0 mg/mL, 250.0 mg/mL

Oral, Tablet, Tablet - Oral, , Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup, Syrup - Oral, Suppository, Rectal, Suppository - Rectal, Solution, Solution - Intramuscular, Liquid, Liquid - Oral, Intramuscular, Intravenous, Liquid - Intramuscular; Intravenous, Liquid - Intravenous, Capsule - Oral, Capsule, Tablet, multilayer - Oral, Tablet, multilayer, Solution - Intramuscular; Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Oral

Nausea

, 50.0 mg, 25.0 mg, 50.0 mg/mL, 15.0 mg, 100.0 mg, 75.0 mg, 15.0 mg/mL, 10.0 mg/mL, 3.0 mg/mL, 250.0 mg/mL

Oral, Tablet, Tablet - Oral, , Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup, Syrup - Oral, Suppository, Rectal, Suppository - Rectal, Solution, Solution - Intramuscular, Liquid, Liquid - Oral, Intramuscular, Intravenous, Liquid - Intramuscular; Intravenous, Liquid - Intravenous, Capsule - Oral, Capsule, Tablet, multilayer - Oral, Tablet, multilayer, Solution - Intramuscular; Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Oral

Acrodynia

, 50.0 mg, 25.0 mg, 50.0 mg/mL, 15.0 mg, 100.0 mg, 75.0 mg, 15.0 mg/mL, 10.0 mg/mL, 3.0 mg/mL, 250.0 mg/mL

Oral, Tablet, Tablet - Oral, , Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup, Syrup - Oral, Suppository, Rectal, Suppository - Rectal, Solution, Solution - Intramuscular, Liquid, Liquid - Oral, Intramuscular, Intravenous, Liquid - Intramuscular; Intravenous, Liquid - Intravenous, Capsule - Oral, Capsule, Tablet, multilayer - Oral, Tablet, multilayer, Solution - Intramuscular; Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Oral

Drug Allergy

, 50.0 mg, 25.0 mg, 50.0 mg/mL, 15.0 mg, 100.0 mg, 75.0 mg, 15.0 mg/mL, 10.0 mg/mL, 3.0 mg/mL, 250.0 mg/mL

Oral, Tablet, Tablet - Oral, , Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup, Syrup - Oral, Suppository, Rectal, Suppository - Rectal, Solution, Solution - Intramuscular, Liquid, Liquid - Oral, Intramuscular, Intravenous, Liquid - Intramuscular; Intravenous, Liquid - Intravenous, Capsule - Oral, Capsule, Tablet, multilayer - Oral, Tablet, multilayer, Solution - Intramuscular; Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Oral

Vertigo

, 50.0 mg, 25.0 mg, 50.0 mg/mL, 15.0 mg, 100.0 mg, 75.0 mg, 15.0 mg/mL, 10.0 mg/mL, 3.0 mg/mL, 250.0 mg/mL

Oral, Tablet, Tablet - Oral, , Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup, Syrup - Oral, Suppository, Rectal, Suppository - Rectal, Solution, Solution - Intramuscular, Liquid, Liquid - Oral, Intramuscular, Intravenous, Liquid - Intramuscular; Intravenous, Liquid - Intravenous, Capsule - Oral, Capsule, Tablet, multilayer - Oral, Tablet, multilayer, Solution - Intramuscular; Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Oral

Gastrointestinal distress

, 50.0 mg, 25.0 mg, 50.0 mg/mL, 15.0 mg, 100.0 mg, 75.0 mg, 15.0 mg/mL, 10.0 mg/mL, 3.0 mg/mL, 250.0 mg/mL

Oral, Tablet, Tablet - Oral, , Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup, Syrup - Oral, Suppository, Rectal, Suppository - Rectal, Solution, Solution - Intramuscular, Liquid, Liquid - Oral, Intramuscular, Intravenous, Liquid - Intramuscular; Intravenous, Liquid - Intravenous, Capsule - Oral, Capsule, Tablet, multilayer - Oral, Tablet, multilayer, Solution - Intramuscular; Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Oral

Nausea

, 50.0 mg, 25.0 mg, 50.0 mg/mL, 15.0 mg, 100.0 mg, 75.0 mg, 15.0 mg/mL, 10.0 mg/mL, 3.0 mg/mL, 250.0 mg/mL

Oral, Tablet, Tablet - Oral, , Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup, Syrup - Oral, Suppository, Rectal, Suppository - Rectal, Solution, Solution - Intramuscular, Liquid, Liquid - Oral, Intramuscular, Intravenous, Liquid - Intramuscular; Intravenous, Liquid - Intravenous, Capsule - Oral, Capsule, Tablet, multilayer - Oral, Tablet, multilayer, Solution - Intramuscular; Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Oral

Nausea

, 50.0 mg, 25.0 mg, 50.0 mg/mL, 15.0 mg, 100.0 mg, 75.0 mg, 15.0 mg/mL, 10.0 mg/mL, 3.0 mg/mL, 250.0 mg/mL

Oral, Tablet, Tablet - Oral, , Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intramuscular; Intravenous, Syrup, Syrup - Oral, Suppository, Rectal, Suppository - Rectal, Solution, Solution - Intramuscular, Liquid, Liquid - Oral, Intramuscular, Intravenous, Liquid - Intramuscular; Intravenous, Liquid - Intravenous, Capsule - Oral, Capsule, Tablet, multilayer - Oral, Tablet, multilayer, Solution - Intramuscular; Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution - Oral

Warnings

Dimenhydrinate Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Dimenhydrinate may interact with Pulse Frequency

There are 20 known major drug interactions with Dimenhydrinate.

Common Dimenhydrinate Drug Interactions

Drug Name

Risk Level

Description

Amiodarone

Major

The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Amiodarone.

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Anagrelide.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Artemether.

Asenapine

Major

The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Asenapine.

Dimenhydrinate Toxicity & Overdose Risk

An overdose of quinine in infants and children may cause hallucinations, seizures, or death. Adults may experience drowsiness, seizures, a coma, or difficulty breathing. Treatment for overdoses of quinine involve providing supportive care and helping with ventilation. The toxic dose of quinine in mice is 203mg/kg when taken orally and 149mg/kg when injected in the abdomen. In rats, the toxic dose is 1320mg/kg when taken orally.

image of a doctor in a lab doing drug, clinical research

Dimenhydrinate Novel Uses: Which Conditions Have a Clinical Trial Featuring Dimenhydrinate?

113 active trials are currently investigating the potential of Dimenhydrinate in alleviating Radiation Therapy induced Nausea and Vomiting, Labyrinthine Dysfunction, and Morning Sickness.

Condition

Clinical Trials

Trial Phases

Nausea and Vomiting

7 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 4

Morning Sickness

1 Actively Recruiting

Phase 3

Nausea

0 Actively Recruiting

Drug Allergy

1 Actively Recruiting

Phase 2

Nausea

0 Actively Recruiting

radiation therapy induced nausea and vomiting

0 Actively Recruiting

Vertigo

7 Actively Recruiting

Not Applicable, Phase 2, Phase 1

Vertigo

3 Actively Recruiting

Phase 4, Not Applicable

Nausea

0 Actively Recruiting

Gastrointestinal distress

9 Actively Recruiting

Phase 2, Early Phase 1, Phase 1, Phase 3, Not Applicable, Phase 4

Airsickness

2 Actively Recruiting

Not Applicable, Phase 3

Labyrinthitis

0 Actively Recruiting

Nausea

5 Actively Recruiting

Phase 2, Phase 3, Phase 1, Not Applicable

Acrodynia

2 Actively Recruiting

Phase 2, Phase 3

Motion Sickness

0 Actively Recruiting

Dimenhydrinate Reviews: What are patients saying about Dimenhydrinate?

5

Patient Review

7/22/2016

Dimenhydrinate for Motion Sickness

I use this product to help me with travel anxiety. It's really effective when taken 30 minutes before the event (be it a car ride or plane flight). I find that it also helps me in general stressors and situations which would normally trigger my anxiety.

5

Patient Review

7/27/2008

Dimenhydrinate for Feel Like Throwing Up

This drug is effective and has the added bonus of making me drowsy.

4.7

Patient Review

4/4/2012

Dimenhydrinate for Motion Sickness

A couple years ago, I tried Dramamine before riding roller coasters at an amusement park and it really worked well for me. I usually get motion sickness easily, but I felt noticeably better throughout the day and after riding the coasters. next time i think i will try the less drowsy formula (meclizine).

4.7

Patient Review

11/29/2010

Dimenhydrinate for Sensation of Spinning or Whirling

I had been feeling really off balance and unsteady, to the point where I was constantly nauseous and vomiting. Thankfully, my doctor diagnosed me with vertigo and prescribed dimenhydrinate. Since treatment, I haven't experienced any of those awful symptoms! I'm so grateful to be able to go about my life without that constant discomfort.

4.3

Patient Review

4/5/2012

Dimenhydrinate for Disease with Hearing Loss, Ringing in the Ears & Dizziness

This tablet has been a godsend during my vertigo attacks. Usually, I see a significant decrease in the intensity of the vertigo within an hour of taking it.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about dimenhydrinate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is dimenhydrinate sedative?

"Dimenhydrinate is a medication that is available in various over-the-counter preparations. The most common side effect associated with its use is sedation."

Answered by AI

Does dimenhydrinate 50 mg make you sleepy?

"Dimenhydrinate is a medication that is used to prevent and treat nausea, vomiting, and dizziness from motion sickness. It is a first-choice option for this purpose, but it can make you very sleepy."

Answered by AI

Is dimenhydrinate Benadryl?

"Antihistamines work by blocking a natural substance called histamine that your body produces.

Dimenhydrinate is not a single drug, but a combination of two drugs, each making up around half of a dose. The two drugs are: Diphenhydramine: This antihistamine is best known as the main ingredient in Benadryl. Antihistamines work by blocking histamine, a natural substance produced by the body."

Answered by AI

What is dimenhydrinate used for?

"Dimenhydrinate is a medication used to prevent and treat nausea, vomiting, and dizziness caused by motion sickness. Dimenhydrinate is an antihistamine, which works by preventing problems with body balance."

Answered by AI

Clinical Trials for Dimenhydrinate

Image of Centre hospitalier de l'Université de Montréal (CHUM) in Montreal, Canada.

Aprepitant for Postoperative Nausea and Vomiting

18+
All Sexes
Montreal, Canada

Postoperative nausea and vomiting (PONV) are a frequent and debilitating complications after surgery, affecting up to 80% of patients at high risk in the absence of prophylaxis. Despite the rigorous application of the recommendations from the American Society of Anesthesiologists (ASA) at CHUM, a recent local study reveals a prevalence of 25% PONV at home after outpatient surgery. However, the therapeutic options at home remain limited. This study aims to evaluate if the addition of 40 mg aprepitant to a multimodal strategy for preventing PONV improves clinical outcomes in high-risk patients undergoing outpatient surgery.

Phase 3
Waitlist Available

Centre hospitalier de l'Université de Montréal (CHUM)

Maxim Roy, MD, FRCPC

Image of Northwestern Memorial Hospital in Chicago, United States.

Emergency Department Physical Therapy for Dizziness

18+
All Sexes
Chicago, IL

This is a multi-site feasibility trial of an embedded emergency department (ED) physical therapy care model for dizziness at two EDs in the Northwestern Medicine and University of Utah Health systems. The study intervention (embedded ED physical therapy) is a reconceptualization of the traditional outpatient physical therapy care model in which we place a physical therapist directly in the ED to initiate timely care for patients with dizziness; we previously evaluated this intervention in a single center randomized trial for low back pain. This multi-site feasibility trial will be comprised of 9 months of active intervention and 12 months of longitudinal data collection. The two sites will be parallel randomized 1:1 to receive either the embedded ED physical therapy condition (intervention, n=1) or usual care (control, n=1) via simple randomization. This trial focuses on feasibility outcomes - such as our ability to enroll participants, deliver the intervention with fidelity, and collect longitudinal patient-reported outcome data and electronic health record data.

Waitlist Available
Has No Placebo

Northwestern Memorial Hospital (+1 Sites)

Image of Endeavor Health in Evanston, United States.

Autonomic Neural Blockade for Postoperative Symptoms in Bariatric Surgery

18 - 90
All Sexes
Evanston, IL

The purpose of this research is to evaluate if autonomic nerve block (ANB- blocking pain and nausea signals) decreases pain and anti-nausea medication requirements as well as the experience of pain/nausea during the first 72 hours after sleeve gastrectomy or gastric bypass surgery. Participants will be randomly assigned either to the standard of care or the ANB group before surgery. As part of standard of care, in both groups, laparoscopic bariatric surgery will be initiated with local anesthetic injected into the abdominal wall. In the ANB group, participants will be given an additional injection of local anesthetic medication to block nerves on and around the stomach.

Waitlist Available
Has No Placebo

Endeavor Health

Herbert Hedberg, MD

Have you considered Dimenhydrinate clinical trials?

We made a collection of clinical trials featuring Dimenhydrinate, we think they might fit your search criteria.
Go to Trials
Image of Montefiore Medical Center in Bronx, United States.

Fosaprepitant vs Metoclopramide for Nausea and Vomiting

18+
All Sexes
Bronx, NY

The study team proposes a double-blind, comparative effectiveness, randomized controlled trial (RCT) to address the following goal: to determine the relative efficacy and adverse event profile of fosaprepitant compared to the standard of care antiemetic metoclopramide. Fosaprepitant and its active metabolite aprepitant are a relatively new class of antiemetic that exclusively acts in the central nervous system by blocking neurokinin (NK-1) which is a key signaling molecule in the centrally mediated aspects of the vomiting reflex. Currently, fosaprepitant and aprepitant both have only two United Stated Food and Drug Administration (USFDA) approved indications for nausea and vomiting: chemotherapy-induced and postoperative. Neurokinin inhibitors are highly effective and generally well-tolerated. Therefore, this class of medication may be a more appropriate medication for the millions of patients with nausea and vomiting that seek care in emergency departments (EDs). Intravenous fosaprepitant is converted to the active metabolite aprepitant on the order of minutes and is significantly cheaper to procure at this time.

Phase 4
Waitlist Available

Montefiore Medical Center (+1 Sites)

Benjamin Friedman, MD

Image of Brigham and Women's Hospital in Boston, United States.

Low Thermal Plasma for Marginal Ulcers

18+
All Sexes
Boston, MA

The objective of the study is to investigate the treatment of marginal ulcers with Low Thermal plasma in an endoscopic setting. By a treatment of the ulcerated areas with argon plasma with low power settings (\~ 1 W) we hypothesize that the size of the ulcers will shrink, and the healing is accelerated compared to standard of care alone. Patients will benefit from this minimally invasive approach compared to a much more invasive surgical approach that comes with higher risks and hospital stay length time. From a societal and scientific perspective, this study aims to extend the well-documented clinical benefits of plasma technology - from external wound healing to internal ulcer treatment - within an endoscopic framework. The success of this study could pave the way for broader applications of LTP in the treatment of other endoscopically accessible conditions such as peptic ulcers, duodenal ulcers and esophageal ulcers. This advancement has the potential not only to improve patient outcomes through less invasive methods, but also to position LTP as a cornerstone in the future of gastroenterological wound management strategies.

Recruiting
Has No Placebo

Brigham and Women's Hospital

Christopher C. Thompson, MD, MSc

Have you considered Dimenhydrinate clinical trials?

We made a collection of clinical trials featuring Dimenhydrinate, we think they might fit your search criteria.
Go to Trials
Image of James A Haley VA Hospital in Tampa, United States.

Vestibular Rehabilitation Therapy for Dizziness from Concussion

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to compare outcomes for standard vestibular rehabilitation home program to a digital vestibular rehabilitation home program in adults with dizziness related to mild traumatic brain injury (mTBI). The main question is whether participants who use the digital format of vestibular rehabilitation improve to a greater extent at discharge than those who use the standard format. Participants will undergo a customized vestibular rehabilitation home exercise program per standard of care, consisting of gaze stabilization, habituation, balance and gait exercises, and endurance training under the supervision of a physical therapist. Participants will complete the gaze stabilization and habituation exercises 2-3 times per day and the balance and gait exercises 1 time per day for 4 weeks. Participants will be tested before and after the 4-week intervention. At the initial session, the researcher will perform standard clinical tests of the inner ear balance system. Also at the initial session, the researcher will perform standard clinical tests of balance and walking and questionnaires about the impact of dizziness on daily activities. At the final session, the researcher will repeat the tests of balance and walking and questionnaires. Three months after completing the intervention participants will complete an online questionnaire about the impact of dizziness on daily activities.

Recruiting
Has No Placebo

James A Haley VA Hospital (+2 Sites)

Have you considered Dimenhydrinate clinical trials?

We made a collection of clinical trials featuring Dimenhydrinate, we think they might fit your search criteria.
Go to Trials